Commercial or open-source closed-loop impact on pregnancy
What this study tests
Observational pregnancy study comparing commercial and open-source closed-loop use in pregnant people with T1D, with registry-listed maternal, neonatal, glycemic, and behavioral/emotional outcomes.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-27.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- See registry for full inclusion/exclusion criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Large for gestational age (LGA)
- Core score on Type 1 Diabetes Distress Assessment Scale (T1-DDAS)
- Hypertensive disorders of pregnancy (HDP)
- Time in pregnancy-specific range (psTIR)
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]